Concepts (296)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epigenesis, Genetic | 5 | 2024 | 291 | 1.590 |
Why?
|
| Hyaluronoglucosaminidase | 16 | 2013 | 20 | 1.260 |
Why?
|
| Neuroglia | 1 | 2024 | 133 | 0.790 |
Why?
|
| Insulin-Secreting Cells | 1 | 2023 | 28 | 0.770 |
Why?
|
| Hyaluronic Acid | 9 | 2013 | 36 | 0.700 |
Why?
|
| Progeria | 5 | 2015 | 9 | 0.680 |
Why?
|
| Ethanol | 5 | 2022 | 224 | 0.640 |
Why?
|
| Parkinson Disease | 5 | 2022 | 210 | 0.590 |
Why?
|
| Neuroprotective Agents | 5 | 2022 | 269 | 0.570 |
Why?
|
| Lamin Type A | 4 | 2005 | 14 | 0.550 |
Why?
|
| Cannabinoids | 1 | 2018 | 73 | 0.530 |
Why?
|
| Cannabis | 1 | 2018 | 90 | 0.500 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 78 | 0.470 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2016 | 83 | 0.450 |
Why?
|
| Transforming Growth Factor beta | 2 | 2016 | 216 | 0.450 |
Why?
|
| Humans | 44 | 2024 | 43102 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 3 | 4 | 2001 | 11 | 0.380 |
Why?
|
| Evolution, Molecular | 2 | 2013 | 307 | 0.370 |
Why?
|
| Antidepressive Agents | 4 | 2022 | 65 | 0.370 |
Why?
|
| DNA Methylation | 2 | 2024 | 403 | 0.310 |
Why?
|
| Signal Transduction | 2 | 2016 | 2157 | 0.310 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2022 | 16 | 0.300 |
Why?
|
| Central Nervous System Depressants | 3 | 2018 | 42 | 0.300 |
Why?
|
| Neuroblastoma | 4 | 2022 | 136 | 0.280 |
Why?
|
| Ejaculation | 1 | 2008 | 11 | 0.280 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 704 | 0.280 |
Why?
|
| Depression | 4 | 2019 | 863 | 0.270 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 94 | 0.270 |
Why?
|
| Fibroblasts | 6 | 2015 | 281 | 0.270 |
Why?
|
| Erectile Dysfunction | 1 | 2008 | 39 | 0.270 |
Why?
|
| Gene Expression Regulation | 5 | 2016 | 1070 | 0.270 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2006 | 13 | 0.240 |
Why?
|
| Lamin Type B | 1 | 2005 | 2 | 0.240 |
Why?
|
| Flavonols | 2 | 2022 | 19 | 0.230 |
Why?
|
| Gene Expression | 4 | 2018 | 701 | 0.220 |
Why?
|
| Embryo, Mammalian | 1 | 2005 | 157 | 0.220 |
Why?
|
| Nicotine | 2 | 2018 | 302 | 0.220 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 43 | 0.210 |
Why?
|
| Stem Cells | 1 | 2005 | 152 | 0.210 |
Why?
|
| Mesoderm | 1 | 2004 | 73 | 0.210 |
Why?
|
| Propionates | 1 | 2024 | 27 | 0.210 |
Why?
|
| Acetaminophen | 1 | 2024 | 30 | 0.210 |
Why?
|
| Valproic Acid | 1 | 2024 | 21 | 0.210 |
Why?
|
| Animals | 15 | 2024 | 16992 | 0.210 |
Why?
|
| Butyrates | 2 | 2022 | 34 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2001 | 7 | 0.200 |
Why?
|
| Olfaction Disorders | 1 | 2023 | 12 | 0.200 |
Why?
|
| Cell Differentiation | 2 | 2005 | 638 | 0.190 |
Why?
|
| Mutation | 2 | 2004 | 1177 | 0.180 |
Why?
|
| Finasteride | 1 | 2022 | 4 | 0.180 |
Why?
|
| Butyric Acid | 1 | 2021 | 19 | 0.180 |
Why?
|
| Receptors, GABA-A | 1 | 2022 | 65 | 0.180 |
Why?
|
| Amino Acid Sequence | 6 | 2004 | 1180 | 0.180 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2000 | 61 | 0.170 |
Why?
|
| Glucose | 1 | 2023 | 244 | 0.170 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2021 | 38 | 0.170 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 141 | 0.170 |
Why?
|
| Cell Survival | 3 | 2020 | 945 | 0.170 |
Why?
|
| Cell Line, Tumor | 7 | 2022 | 2676 | 0.170 |
Why?
|
| Neurons | 2 | 2024 | 1263 | 0.160 |
Why?
|
| Peptide Fragments | 2 | 2019 | 307 | 0.160 |
Why?
|
| Tetanus Toxin | 1 | 2019 | 3 | 0.150 |
Why?
|
| Antiparkinson Agents | 1 | 2019 | 14 | 0.150 |
Why?
|
| Nerve Growth Factors | 1 | 2019 | 34 | 0.150 |
Why?
|
| Ketamine | 1 | 2018 | 13 | 0.150 |
Why?
|
| Cytoprotection | 1 | 2018 | 36 | 0.150 |
Why?
|
| Indans | 1 | 2018 | 14 | 0.140 |
Why?
|
| Isoenzymes | 2 | 2002 | 168 | 0.140 |
Why?
|
| Cell Line | 5 | 2005 | 1410 | 0.140 |
Why?
|
| Piperidines | 1 | 2018 | 83 | 0.140 |
Why?
|
| Genome, Human | 2 | 2013 | 144 | 0.130 |
Why?
|
| Manganese | 1 | 2018 | 92 | 0.130 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 199 | 0.130 |
Why?
|
| Caspase 3 | 1 | 2018 | 227 | 0.130 |
Why?
|
| Imipramine | 1 | 2017 | 9 | 0.130 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2017 | 15 | 0.130 |
Why?
|
| Molecular Sequence Data | 5 | 2001 | 1542 | 0.130 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2017 | 17 | 0.130 |
Why?
|
| Marijuana Abuse | 1 | 2018 | 100 | 0.130 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2017 | 39 | 0.130 |
Why?
|
| Vasodilator Agents | 2 | 2008 | 55 | 0.130 |
Why?
|
| Iron | 1 | 2018 | 251 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 187 | 0.130 |
Why?
|
| Neurotransmitter Agents | 1 | 2017 | 69 | 0.130 |
Why?
|
| Sclera | 1 | 2016 | 6 | 0.120 |
Why?
|
| Psychosurgery | 1 | 2016 | 1 | 0.120 |
Why?
|
| Sterilization | 1 | 2016 | 3 | 0.120 |
Why?
|
| Hungary | 1 | 2016 | 9 | 0.120 |
Why?
|
| Portugal | 1 | 2016 | 10 | 0.120 |
Why?
|
| Trabecular Meshwork | 1 | 2016 | 10 | 0.120 |
Why?
|
| History, 19th Century | 1 | 2016 | 25 | 0.120 |
Why?
|
| Optic Nerve | 1 | 2016 | 30 | 0.120 |
Why?
|
| Aqueous Humor | 1 | 2016 | 18 | 0.120 |
Why?
|
| Ethics, Medical | 1 | 2016 | 18 | 0.120 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 38 | 0.120 |
Why?
|
| Microarray Analysis | 1 | 2016 | 64 | 0.120 |
Why?
|
| Nicotinic Agonists | 1 | 2017 | 88 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2016 | 121 | 0.120 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2017 | 126 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 1997 | 290 | 0.120 |
Why?
|
| Cell Nucleus | 2 | 2010 | 383 | 0.120 |
Why?
|
| Bacteria | 1 | 2018 | 293 | 0.120 |
Why?
|
| Mucopolysaccharidoses | 2 | 2008 | 3 | 0.120 |
Why?
|
| Fibrosis | 1 | 2016 | 169 | 0.120 |
Why?
|
| Intraocular Pressure | 1 | 2016 | 132 | 0.110 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2001 | 267 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 1124 | 0.110 |
Why?
|
| Computational Biology | 1 | 2016 | 327 | 0.100 |
Why?
|
| Chondroitin | 1 | 2013 | 1 | 0.100 |
Why?
|
| Chitin | 1 | 2013 | 20 | 0.100 |
Why?
|
| Enzyme Inhibitors | 4 | 2010 | 458 | 0.100 |
Why?
|
| Selection Bias | 1 | 2012 | 13 | 0.100 |
Why?
|
| Peer Review, Research | 1 | 2012 | 15 | 0.100 |
Why?
|
| Editorial Policies | 1 | 2012 | 14 | 0.100 |
Why?
|
| Science | 1 | 2012 | 24 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2008 | 1604 | 0.090 |
Why?
|
| Male | 10 | 2022 | 23409 | 0.090 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 52 | 0.090 |
Why?
|
| Depressive Disorder | 2 | 2019 | 187 | 0.090 |
Why?
|
| Syndrome | 3 | 2010 | 73 | 0.090 |
Why?
|
| Aging | 2 | 2015 | 783 | 0.080 |
Why?
|
| Farnesyltranstransferase | 1 | 2010 | 4 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 830 | 0.080 |
Why?
|
| Extracellular Matrix | 2 | 2004 | 131 | 0.080 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2010 | 40 | 0.080 |
Why?
|
| Phenotype | 3 | 2015 | 780 | 0.080 |
Why?
|
| Mice | 5 | 2008 | 6644 | 0.080 |
Why?
|
| DNA Repair | 1 | 2010 | 198 | 0.070 |
Why?
|
| Blotting, Northern | 2 | 1999 | 150 | 0.070 |
Why?
|
| Skin | 2 | 2000 | 187 | 0.070 |
Why?
|
| Rats, Inbred WKY | 2 | 2019 | 17 | 0.070 |
Why?
|
| Orgasm | 1 | 2008 | 2 | 0.070 |
Why?
|
| Osteoarthritis | 1 | 2008 | 25 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 33 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2004 | 652 | 0.070 |
Why?
|
| Rats, Wistar | 2 | 2018 | 283 | 0.060 |
Why?
|
| DNA Mutational Analysis | 2 | 2004 | 95 | 0.060 |
Why?
|
| Base Sequence | 3 | 2004 | 983 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 734 | 0.060 |
Why?
|
| Child | 3 | 2022 | 3443 | 0.060 |
Why?
|
| Rats | 3 | 2019 | 3735 | 0.060 |
Why?
|
| Citalopram | 1 | 2006 | 3 | 0.060 |
Why?
|
| Ergolines | 1 | 2006 | 2 | 0.060 |
Why?
|
| Sertraline | 1 | 2006 | 7 | 0.060 |
Why?
|
| Selegiline | 1 | 2006 | 6 | 0.060 |
Why?
|
| Bupropion | 1 | 2006 | 13 | 0.060 |
Why?
|
| Fluoxetine | 1 | 2006 | 15 | 0.060 |
Why?
|
| Purines | 1 | 2006 | 40 | 0.060 |
Why?
|
| Central Nervous System Stimulants | 1 | 2008 | 180 | 0.060 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2006 | 28 | 0.060 |
Why?
|
| Muscle Cells | 1 | 2005 | 12 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2006 | 34 | 0.060 |
Why?
|
| Sulfones | 1 | 2006 | 47 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1596 | 0.060 |
Why?
|
| Plants, Medicinal | 1 | 2006 | 57 | 0.060 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2006 | 83 | 0.060 |
Why?
|
| Androgens | 1 | 2006 | 106 | 0.060 |
Why?
|
| Piperazines | 1 | 2006 | 120 | 0.060 |
Why?
|
| Adult | 5 | 2015 | 13872 | 0.060 |
Why?
|
| Cell Lineage | 1 | 2005 | 104 | 0.060 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2006 | 70 | 0.060 |
Why?
|
| Testosterone | 1 | 2006 | 211 | 0.050 |
Why?
|
| Female | 8 | 2017 | 24698 | 0.050 |
Why?
|
| Hippocampus | 2 | 2019 | 594 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2004 | 536 | 0.050 |
Why?
|
| Heterozygote | 1 | 2004 | 110 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2002 | 508 | 0.050 |
Why?
|
| Substrate Specificity | 3 | 2001 | 219 | 0.050 |
Why?
|
| Anxiety | 2 | 2015 | 874 | 0.050 |
Why?
|
| Werner Syndrome | 1 | 2003 | 3 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 256 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2004 | 150 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 333 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2008 | 1035 | 0.050 |
Why?
|
| Point Mutation | 1 | 2003 | 98 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2022 | 55 | 0.050 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2022 | 81 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2004 | 456 | 0.050 |
Why?
|
| Chondrogenesis | 1 | 2002 | 4 | 0.050 |
Why?
|
| Homozygote | 2 | 2003 | 77 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2003 | 58 | 0.050 |
Why?
|
| RNA | 1 | 2004 | 266 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2002 | 69 | 0.050 |
Why?
|
| Isotretinoin | 1 | 2022 | 4 | 0.050 |
Why?
|
| Pseudogenes | 1 | 2001 | 12 | 0.050 |
Why?
|
| Gene Duplication | 1 | 2001 | 24 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2015 | 1621 | 0.040 |
Why?
|
| Adolescent | 2 | 2022 | 6081 | 0.040 |
Why?
|
| Multigene Family | 1 | 2001 | 105 | 0.040 |
Why?
|
| Genotype | 1 | 2004 | 800 | 0.040 |
Why?
|
| Time Factors | 1 | 2006 | 1857 | 0.040 |
Why?
|
| Species Specificity | 1 | 2001 | 286 | 0.040 |
Why?
|
| Dopamine | 1 | 2022 | 275 | 0.040 |
Why?
|
| Genome | 1 | 2001 | 149 | 0.040 |
Why?
|
| Cloning, Molecular | 2 | 1998 | 314 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2001 | 518 | 0.040 |
Why?
|
| RNA Precursors | 1 | 2000 | 28 | 0.040 |
Why?
|
| Gene Library | 1 | 1999 | 62 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2000 | 94 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2004 | 735 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1285 | 0.040 |
Why?
|
| Cell Death | 1 | 2020 | 278 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 81 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2000 | 166 | 0.040 |
Why?
|
| Intestines | 1 | 2018 | 71 | 0.040 |
Why?
|
| Locomotion | 1 | 2019 | 105 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 186 | 0.040 |
Why?
|
| Sequence Tagged Sites | 1 | 1998 | 4 | 0.040 |
Why?
|
| Models, Biological | 1 | 2001 | 712 | 0.030 |
Why?
|
| Feces | 1 | 2018 | 132 | 0.030 |
Why?
|
| Databases, Factual | 1 | 1999 | 341 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2019 | 121 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1998 | 122 | 0.030 |
Why?
|
| Phylogeny | 1 | 2001 | 769 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 1997 | 68 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2018 | 195 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 1997 | 54 | 0.030 |
Why?
|
| Fluoresceins | 1 | 2017 | 29 | 0.030 |
Why?
|
| Leeches | 1 | 1997 | 1 | 0.030 |
Why?
|
| Invertebrates | 1 | 1997 | 15 | 0.030 |
Why?
|
| Eukaryota | 1 | 1997 | 20 | 0.030 |
Why?
|
| Swimming | 1 | 2017 | 41 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2017 | 104 | 0.030 |
Why?
|
| Venoms | 1 | 1997 | 18 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 737 | 0.030 |
Why?
|
| Viruses | 1 | 1997 | 39 | 0.030 |
Why?
|
| Bacteriophages | 1 | 1997 | 44 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 455 | 0.030 |
Why?
|
| Motor Activity | 1 | 2019 | 437 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 1997 | 306 | 0.030 |
Why?
|
| Fungi | 1 | 1997 | 106 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 103 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 491 | 0.030 |
Why?
|
| Observer Variation | 1 | 2012 | 59 | 0.020 |
Why?
|
| Apoptosis | 1 | 2020 | 1568 | 0.020 |
Why?
|
| Middle Aged | 1 | 2008 | 12222 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 609 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1998 | 495 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 1997 | 595 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1154 | 0.020 |
Why?
|
| Exons | 2 | 2003 | 92 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 1472 | 0.020 |
Why?
|
| Neoplasms | 1 | 2001 | 1377 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2001 | 388 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1455 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 2000 | 196 | 0.020 |
Why?
|
| Joints | 1 | 2008 | 13 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 2008 | 24 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2008 | 39 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 3994 | 0.020 |
Why?
|
| Uniparental Disomy | 1 | 2003 | 3 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2003 | 12 | 0.010 |
Why?
|
| RNA Splice Sites | 1 | 2003 | 10 | 0.010 |
Why?
|
| Electrophoresis | 1 | 2003 | 24 | 0.010 |
Why?
|
| Pedigree | 1 | 2003 | 94 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 102 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 196 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2002 | 98 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2002 | 129 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2002 | 158 | 0.010 |
Why?
|
| Staurosporine | 1 | 2002 | 38 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2002 | 44 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2002 | 83 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 458 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 611 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2002 | 112 | 0.010 |
Why?
|
| Microchemistry | 1 | 2001 | 10 | 0.010 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2001 | 22 | 0.010 |
Why?
|
| Biotin | 1 | 2001 | 24 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 465 | 0.010 |
Why?
|
| Gels | 1 | 2001 | 45 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2003 | 403 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 197 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2000 | 52 | 0.010 |
Why?
|
| Skin Absorption | 1 | 2000 | 16 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1999 | 8 | 0.010 |
Why?
|
| Epidermis | 1 | 2000 | 23 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1999 | 52 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1999 | 43 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 49 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2000 | 79 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2000 | 114 | 0.010 |
Why?
|
| Introns | 1 | 2000 | 79 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1999 | 39 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1999 | 168 | 0.010 |
Why?
|
| Cell Count | 1 | 1999 | 145 | 0.010 |
Why?
|
| Testis | 1 | 2001 | 207 | 0.010 |
Why?
|
| Cattle | 1 | 2001 | 498 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 695 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 152 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2001 | 570 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1999 | 462 | 0.010 |
Why?
|
| Insulin | 1 | 1999 | 258 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1997 | 26 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 1271 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2000 | 526 | 0.010 |
Why?
|